TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00720109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study: NCT01697618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
Study: NCT04096976

Intervention type: OTHER
Intervention: logistic regression
Description: To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression

Intervention type: OTHER
Intervention: logistic regression
Description: To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
Study: NCT02802267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inecalcitol
Description: vitamin D receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study: NCT02292836

Intervention type: OTHER
Intervention: Questionnaire testing
Description: Questionnaire testing on rosacea and non-rosacea dermatology outpatients

Intervention type: OTHER
Intervention: Questionnaire testing
Description: Questionnaire testing on rosacea and non-rosacea dermatology outpatients
Study: NCT00720109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT03156387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: 2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
Study: NCT01617746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 5mg od two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5mg bd two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bd for two weeks
Study: NCT03563183

Intervention type: OTHER
Intervention: Encoding of data collected in Zoster 006 and Zoster 022 studies
Description: Not applicable (disease epidemiology study)
Study: NCT01942733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
Study: NCT00192634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine 200mg - Tenofovir 300mg
Description: 1 tablet once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir 600mg - Lamivudine 300mg
Description: 1 tablet once daily for 96 weeks
Study: NCT01543633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
Study: NCT00838513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study: NCT01491984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy order: 1) MAC, 2) Levitan
Description: Laryngoscopy with MAC, then Levitan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy order: 1) MAC, 2) Levitan
Description: Laryngoscopy with MAC, then Levitan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy order: 1) Levitan, 2) MAC
Description: Laryngoscopy with Levitan, then MAC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy order: 1) Levitan, 2) MAC
Description: Laryngoscopy with Levitan, then MAC
Study: NCT05162937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-17A antibody
Description: Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-17A antibody
Description: Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-17A antibody
Description: Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IL-17A antibody
Description: Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
Study: NCT01594528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain tests
Description: pain induction with pressure application or ischemia on the arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain tests
Description: pain induction with pressure application or ischemia on the arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain tests
Description: pain induction with pressure application or ischemia on the arm
Study: NCT00486291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 15mg/topiramate 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT02497742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic metabolic panel
Description: Patients blood is collected in routine fashion for basic blood chemistries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic metabolic panel
Description: Patients blood is collected in routine fashion for basic blood chemistries
Study: NCT04135287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
Study: NCT04088058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GXHPC1
Description: autologous ADSCs
Study: NCT04588454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET tracer
Description: 18F-PSMA-1007 PET/CT
Study: NCT01931371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Fistula Plug
Description: Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Fistula Plug
Description: Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endorectal Advancement Flap
Description: Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endorectal Advancement Flap
Description: Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
Study: NCT05118880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Bullying Counseling Program based on the Interpersonal Relationship Model
Description: The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques.
Study: NCT04625517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Mammography
Description: Digital Mammography enhanced with an iodinated contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
Description: Injection of low osmolar contrast material during the digital mammography exam
Study: NCT04346355

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
Study: NCT03961009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kedrion IVIG 10%
Description: Kedrion intravenous immunoglobulin (IVIg) 10%
Study: NCT01695759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprex
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
Study: NCT00950820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Capecitabine, Panitumumab
Description: Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin, Capecitabine
Description: The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin, Capecitabine
Description: The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Study: NCT02090842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-caseinate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Study: NCT01757015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 (50µg, o.d. via SDDPI) in the morning,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237
Description: Placebo to NVA237
Study: NCT00066456

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemosensitization/Potentiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT02628977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Based Sleep Health Education and Social Support
Description: Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
Study: NCT04009382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise
Description: Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Fitness Program
Description: Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
Study: NCT00362232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo: tablet of Rivaroxaban
Description: Placebo tablet of rivaroxaban administered once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo: syringes of Enoxaparin
Description: Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
Study: NCT02700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation--CD34 HSCT
Description: Undergo autologous CD34 HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation--AHSCT
Description: Undergo AHSCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation--AHSCT
Description: Undergo AHSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Undergo autologous CD34 HSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid Vaccine
Description: Given IM
Study: NCT00720109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study: NCT03816046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: injection in hair bearing area of armpits
Study: NCT00720109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00720109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV
Study: NCT02090842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Study: NCT03716154

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Diode laser 810nm, 2W, 20sec, 20 HZ
Study: NCT00607490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
Study: NCT00720109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM
Study: NCT00607490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
Study: NCT01646229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polymyxin-B hemoperfusion
Study: NCT00375752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg.tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg.tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolendronic Acid
Description: 4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
Study: NCT01646229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT02034006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
Study: NCT00750269

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 40.0 Gy
Description: SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 42.5 Gy
Description: SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 45.0 Gy
Description: SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 47.5 Gy
Description: SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 50.0 Gy
Description: SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 52.5 Gy
Description: SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
Study: NCT02931773

Intervention type: DEVICE
Intervention: Task Force® Monitor
Description: A head up tilt test carried out with a Task Force monitoring system

Intervention type: DEVICE
Intervention: Task Force® Monitor
Description: A head up tilt test carried out with a Task Force monitoring system
Study: NCT00750269

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 55.0 Gy
Description: SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 57.5 Gy
Description: SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 60.0 Gy
Description: SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
Study: NCT04326374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon hGH
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daily hGH
Description: Once daily subcutaneous injection
Study: NCT02931773

Intervention type: DEVICE
Intervention: Task Force® Monitor
Description: A head up tilt test carried out with a Task Force monitoring system
Study: NCT04555447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agavins (prebiotic fiber)
Description: Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agavins (prebiotic fiber)
Description: Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
Study: NCT01612832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: pain treatment as customary in the department
Study: NCT04555447

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.